

Like **GETTING** the **BADDY**
and **KISSING** the **GIRL**
and **RIDING** into the **SUNSET**

**IT'S GOT THE
INGREDIENTS OF A CLASSIC**



 **TESTOGEL**[®]
testosterone

PRESCRIBING INFORMATION Testogel[®] (testosterone) Presentation: Sachet containing 50mg testosterone in 5g colourless gel. **Uses:** Testosterone replacement therapy for male hypogonadism when testosterone deficiency confirmed by clinical features and biochemical tests. **Dosage:** One 5g gel sachet daily. Can be adjusted in 2.5g gel steps, to a maximum of 10g gel daily. Once sachet opened, apply immediately onto clean, dry healthy skin over both shoulders, or both arms or abdomen. Do not apply to genital areas. **Children:** Not for use in children. Not evaluated clinically in males under 18. **Contra-indications:** Known or suspected prostate or breast cancer. Hypersensitivity to testosterone or any constituents of the gel. **Warnings and precautions:** Before therapy exclude prostate cancer. Examine prostate and breast at least annually, or twice yearly in elderly or at risk patients (clinical or familial factors). Monitor serum calcium concentrations in cancer patients at risk of hypercalcaemia (and hypercalcaemia). Testogel may cause oedema with or without congestive cardiac failure in patients with severe cardiac, hepatic or renal insufficiency. In this case, stop treatment immediately. Use with caution in patients with ischaemic heart disease, hypertension, epilepsy and migraine. Periodically check testosterone concentrations, haemoglobin, haematocrit, liver function (tests), lipid profile. Possible increased risk of sleep apnoea especially if obesity or chronic respiratory disease present. Improved insulin sensitivity may occur. Irritability, nervousness, weight gain, prolonged or frequent erections may indicate excessive androgen exposure requiring dose adjustment. If severe application site reactions occur, discontinue if necessary. Testosterone may produce a positive reaction in anti-doping tests. Not for use in women. Testosterone gel can be transferred to others by close skin to skin contact and can lead to adverse effects (inadvertent androgenisation) if repeated contact. Inform patient of transfer risk that is prevented by clothing or washing of application site. Testogel should not be prescribed for patients who may not comply with safety instructions (e.g.

alcoholics, drug abusers, psychiatric patients). Pregnant women must avoid any contact with the application sites. Interactions reported with oral anticoagulants, ACTH or corticosteroids, and thyroxin binding globulin in laboratory tests. **Side-effects:** Most common (10%) were: skin reactions. Also reported were: changes in laboratory tests (polycythaemia, lipids), headache, prostatic disorders, gynaecomastia, mastodynia, dizziness, paraesthesia, amnesia, hyperaesthesia, mood disorders, hypertension, diarrhoea, alopecia, urticaria. Other known reactions to testosterone treatments are: muscle cramps; nervousness; depression; hostility; sleep apnoea; skin reactions; libido changes; more frequent erections; hypersensitivity reactions; rarely: jaundice, liver function tests, priapism, prostate abnormalities, prostate cancer (inconclusive), urinary obstruction. During high dose and/or prolonged treatment: weight gain, electrolyte changes, reversible interruption or reduction of spermatogenesis, water retention, oedema, rarely: hepatic neoplasms. Frequent applications may cause irritation and dry skin. **Basic NHS Price:** £33.00 per pack of 30 x 5g sachets **Legal Classification:** POM **Product Licence Number:** 16468/0005 **Product Licence Holder:** Laboratoires BESINS INTERNATIONAL 5, rue du Bourg L'Abbé 75003 Paris France **Distributed by:** Bayer plc, Bayer House, Strawberry Hill, Newbury, Berkshire RG14 1JA **Testogel is a registered trademark of Laboratoires BESINS INTERNATIONAL PI revised:** 1 May 2008 8TESTO2c March 2008

Information about adverse reaction reporting in the UK can be found at www.yellowcard.gov.uk. Alternatively, adverse reactions can be reported to Bayer plc by email: phdsguk@bayer.co.uk



Society for Endocrinology Clinical Update



**CU
08**

6-8 October 2008

Bristol Royal Marriott, Bristol

Second of a new series of clinical training events providing essential training for all trainees and new consultants and an excellent forum for networking opportunities with peers and established endocrinologists.

Over a 3 year period, the programme covers the new national curriculum in endocrinology and diabetes and is fast becoming the UK's premier clinical training event.

Interactive workshops including case-based studies will cover a wide range of topics; provisionally, these are:

Disorders of the hypothalamus and pituitary

Growth and development

Disorders of the thyroid gland

Disorders of the adrenal gland

Disorders of the gonads

**Disorders of the parathyroid glands,
calcium metabolism and bone**

Disorders of appetite, weight and metabolism

Miscellaneous endocrine disorders and oncology

In collaboration with the Dutch Endocrine Society and
in association with the Clinical Endocrinology Trust

For further information please visit



**CU
08**

www.endocrinology.org/meetings/2008/clinicalupdate2008/index.html